Last reviewed · How we verify
ALV003
At a glance
| Generic name | ALV003 |
|---|---|
| Sponsor | Alvine Pharmaceuticals Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients (PHASE2)
- Study of Latiglutenase in T1D/CD Patients (PHASE2)
- Latiglutenase as a Treatment for Celiac Disease (PHASE2)
- Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients (PHASE2)
- Safety and Efficacy of ALV003 for the Treatment of Celiac Disease (PHASE2)
- Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease (PHASE2)
- Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal (PHASE1)
- A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALV003 CI brief — competitive landscape report
- ALV003 updates RSS · CI watch RSS
- Alvine Pharmaceuticals Inc. portfolio CI